Center for Advanced Imaging Innovation and Research (CAI2R)

项目摘要 P41 EB 017183的竞争修订版 先进成像创新与研究中心（CAI 2 R）的使命是让人们 一起创造新的观看方式。我们中心的工作重点是创造新的范例， 用于生物医学图像的采集、重建和解释，以及实施新的 合作模式，以便将这些发展迅速转化为临床实践。 在拟议的竞争修订中，我们将运用我们在生物医学图像方面的经验， 新合作的其他信号，旨在满足COVID-19检测的迫切需求。 家长资助摘要 生物医学成像的世界正在发生变化，CAI 2 R一直处于这一变化的最前沿。任务 曾经是唯一的领域，精心设计的成像硬件，现在开始成为 在软件中完成，越来越多地由各种廉价的辅助传感器阵列提供信息。信息 曾经通过费力地获取仔细分离的图像数据集来实现的 从新整合的、丰富的定量数据流中。为配合这些主题，我们的中心将 围绕以下四个技术研究与开发（TR&D）项目组织： 1.重新构想扫描的未来：智能图像采集、重建和分析。 2.解开未来扫描仪的枷锁：灵活、自校正、多传感器机器。 3.丰富数据流：MRI和PET的协同作用。 4.揭示微观结构：用于发现和临床护理的生物物理建模和验证。 竞争版本摘要 随着COVID-19的出现，世界突然发生了变化。需要明确但广泛地 可用的COVID-19检测是明确的，并在特别关注通知（NOT-EB-4）中被确定为首要任务。 #20 -008;，这是我的建议。在这个项目中，我们将与化学领域的同事合作， 工程和病毒学，以开发，评估和部署一种新的电化学装置，用于多方面的点， 护理或家庭COVID-19检测。该设备将使用分子表面印迹来创建一个黄金 表面对SARS-CoV-2刺突蛋白和其他感兴趣的分析物敏感。敏感固态 然后，电子设备将检测患者样品中这些分析物的存在，最终允许快速和 同时评估COVID-19感染、免疫力和严重程度。竞争的具体目标 修订如下： 1.样机我们将测试是否已经使用我们最好的电流获得COVID-19信号 压印方法和电子检测电路。 2.描述一下我们将使用生物样本库的患者样本来建立灵敏度、特异性和限度， 检测（LOD）我们的初始原型COVID-19，而不是其他常见病毒。 3.优化和优化。根据目标1和2，我们将开发优化的电子产品，表面压印， 协议和测量策略，以提高灵敏度和特异性。 4.评估和分发。我们将在一个队列中前瞻性地测试具有良好性能的设计， 受试者在纽约大学进行检测，并将结果与标准RT-PCR COVID-19检测进行比较， 着眼于FDA的批准、商业化和更广泛的分销。

PROJECT SUMMARY Competitive Revision to P41 EB017183 The Center for Advanced Imaging Innovation and Research (CAI2R) pursues a mission of bringing people together to create new ways of seeing. The work of our Center has been focused on creating new paradigms for the acquisition, reconstruction, and interpretation of biomedical images, and on implementing new collaboration models in order to translate these developments rapidly into clinical practice. In the proposed Competitive Revision, we will apply our experience in working with biomedical images and other signals to a new collaboration, aimed at the urgent need for COVID-19 testing. Parent Grant Summary The world of biomedical imaging is changing, and CAI2R has been at the forefront of that change. Tasks that were once the sole domain of meticulously-engineered imaging hardware are now beginning to be accomplished in software, increasingly informed by diverse arrays of inexpensive auxiliary sensors. Information once pursued through the laborious acquisition of carefully separated image datasets is now being derived from newly integrated, and richly quantitative, data streams. In keeping with these themes, our Center will be organized around the following four Technology Research and Development (TR&D) projects going forward: 1. Reimagining the Future of Scanning: Intelligent image acquisition, reconstruction, and analysis. 2. Unshackling the Scanners of the Future: Flexible, self-correcting, multisensor machines. 3. Enriching the Data Stream: MRI and PET in concert. 4. Revealing Microstructure: Biophysical modeling and validation for discovery and clinical care. Competitive Revision Summary With the appearance of COVID-19, the world changed suddenly. The need for definitive but also broadly available COVID-19 testing is clear, and is identified as a top priority in the Notice of Special Interest (NOT-EB- 20-008) to which this proposal responds. In this project, we will partner with colleagues in chemical engineering and virology to develop, evaluate, and deploy a new electrochemical device for multifaceted point- of-care or home-based COVID-19 testing. The device will use molecular surface imprinting to create a gold surface sensitive to SARS-CoV-2 spike proteins and other analytes of interest. Sensitive solid-state electronics will then detect the presence of these analytes in patient samples, ultimately allowing rapid and simultaneous assessment of COVID-19 infection, immunity and severity. Specific Aims of the Competitive Revision are as follows: 1. Prototype. We will test whether a COVID-19 signal may already be obtained using our best current imprinting methods and electronic detection circuitry. 2. Characterize. We will use biobanked patient samples to establish sensitivity, specificity, and limits of detection (LOD) of our initial prototype for COVID-19, as opposed to other common viruses. 3. Optimize and iterate. Informed by Aims 1 and 2, we will develop optimized electronics, surface imprinting protocols, and measurement strategies to improve sensitivity and specificity. 4. Evaluate and distribute. We will test designs with promising performance prospectively in a cohort of subjects presenting for testing at NYU, and will compare results with standard RT-PCR COVID-19 testing, with an eye towards FDA approval, commercialization, and broader distribution.